PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025
news

Scientists home in on cause of Duchenne gene therapy side effect

Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of...
Continue Reading →
news

Scientists home in on cause of Duchenne gene therapy side effect

Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of...
Continue Reading →
news

Undeterred by gene therapy’s struggles, a startup launches into a downturn

Gene therapy companies have been especially vulnerable to a public market downturn that’s shaken the biotech sector. But the difficult environment hasn’t stopped vent...
Continue Reading →
news

Solid Bio joins slate of biotech layoffs, shedding 35% of its workforce

Dive Brief: Gene therapy developer Solid Biosciences is laying off 35% of its employees, announcing Wednesday a plan to extend its current funds for another two ye...
Continue Reading →
news

Regeneron, in search of an eye gene therapy, turns to a young biotech

Dive Brief: Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal d...
Continue Reading →
news

Orchard turns to layoffs in cutting gene therapy research

Dive Brief: Orchard Therapeutics, a London- and Boston-based developer of gene therapies, plans to lay off 30% of its workforce, or about 65 employees, as it moves...
Continue Reading →
news

As biotech retreats, gene therapy companies retrench and redraw plans

Bluebird bio has spent the better part of two decades developing gene therapies for rare diseases. This summer, after years of clinical trials, setbacks and delays, t...
Continue Reading →
news

Spark CEO Marrazzo, who led company to historic gene therapy approval, to step down

Jeffrey Marrazzo, CEO of gene therapy developer Spark Therapeutics, will step down as head of the company he co-founded almost nine years ago, steered to a historic F...
Continue Reading →
news

In England, Orchard secures rare agreement on gene therapy coverage

Dive Brief: The National Health Service in England and Wales will cover treatment with an exceptionally high-priced gene therapy for a rare and fatal genetic disea...
Continue Reading →
news

Gene editing startup Metagenomi raises $175M to advance research pipeline

Metagenomi, a biotech startup that three months ago struck a research alliance with Moderna, has raised $175 million to expand and build on its early research explori...
Continue Reading →
Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40